Comparative Pharmacology
Head-to-head clinical analysis: DURAGESIC 50 versus LERITINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURAGESIC 50 versus LERITINE.
DURAGESIC-50 vs LERITINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a potent synthetic opioid agonist primarily at μ-opioid receptors, with additional weak affinity for κ- and δ-opioid receptors. It increases potassium conductance and decreases calcium influx, leading to hyperpolarization and reduced neurotransmitter release, resulting in analgesia and sedation.
LERITINE (anileridine) is a synthetic opioid analgesic that acts as a mu-opioid receptor agonist, modulating pain perception and emotional response to pain.
Apply one 50 mcg/h transdermal system every 72 hours; initiate at 25 mcg/h in opioid-naive patients; titrate based on response and tolerability.
Adults: 25-50 mg orally every 6 hours as needed for pain; not to exceed 200 mg/day.
None Documented
None Documented
Mean terminal elimination half-life 20–27 h (range 13–40 h). Prolonged with hepatic impairment, elderly, or obesity. Clinical context: Requires ~5 days to reach steady state; accumulation risk with continuous use.
2-3 hours (terminal half-life in adults; may be prolonged in hepatic impairment or elderly, dosing adjustments recommended)
Primarily renal: ~75% as metabolites (mostly norfentanyl, <10% unchanged fentanyl); ~9% biliary/fecal; <10% excreted in urine as unchanged drug.
Renal (70-90% as unchanged drug and metabolites); biliary/fecal (10-30%)
Category C
Category C
Opioid Analgesic
Opioid Analgesic